Personal Precise Treatment on Psoriasis and Psoriatic Arthritis

Taichung Veterans General Hospital90 enrolled

Overview

Part of psoriasis and psoriatic arthritis patients treated with biologics and met primary failure. Therefore, we are going to create a cell based platform to evaluate the treatment effects of different biologics on psoriasis and psoriatic arthritis patients before prescribed by physicians

PBMCs isolated from psoriasis and psoriatic arthritis and incubated with Group A streptococcus and different biologics for 24 hours. Cytokines expression in the culture supernatants will be measured and the data can be reference for physician's prescription.

Study Type

INTERVENTIONAL

Allocation

Purpose

SCREENING

Masking

NONE

Enrollment

Conditions

Dermatologic Disease

Interventions

Markers data from PBMCsDIAGNOSTIC_TEST

Prescreen markers from patient individual PBMCs treating with streptococcus and different biologics.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * 1\. Healthy control without underline disease such as psoriasis and psoriatic arthritis. 2. Psoriasis been diagnosed for over six months and PASI \>10. 3.Psoriatic arthritis been diagnosed for over six months and \>1 swallow and tender joints Exclusion Criteria: * nil

Outcomes

Primary Outcomes

PASI score

Psoriasis skin condition and severity

Time frame: 2 weeks to 3 months

swelling joint count and tenderness joint count

PSA severity

Time frame: 2 weeks to 3 months

Secondary Outcomes

CRP

blood test

Time frame: 3-6 months

DLQI

paper to investigate patient life quality

Time frame: 6 months

Central Contacts

Chung-Yang Yen, MDPhD

CONTACT

886423592525 vernayen@yahoo.com.tw

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.